Aidea Pharma(SH:688488) 智通财经网·2026-02-24 09:37Core Viewpoint - The company reported a significant increase in total revenue for the fiscal year 2025, driven by the growth in innovative HIV drug sales and the consolidation of Nanda Pharmaceutical's operational data [1] Group 1: Financial Performance - Total revenue for the year reached 721 million yuan, representing a year-on-year increase of 72.49% [1] - The net profit attributable to the parent company was a loss of 19.73 million yuan, with the loss margin decreasing by 86.02% compared to the previous year [1] Group 2: Key Drivers of Performance - The increase in gross profit from core operations was approximately 255 million yuan compared to the previous year, attributed to higher revenue from innovative HIV drugs and the consolidation of Nanda Pharmaceutical [1] - Sales expenses increased by approximately 92 million yuan year-on-year due to intensified new drug promotion efforts and the inclusion of Nanda Pharmaceutical's operational data [1] - Asset impairment losses decreased by approximately 48 million yuan compared to the previous year, as market expansion and expectations stabilized [1]